Physician profile
Molly E Warnock
NPI 1821628751
$7,842.38
in general payments reported to CMS, 2019-2025
30 companies · $2,246 in 2025
The $2,246 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $971 · 2022: $976 · 2023: $1,759 · 2024: $1,890 · 2025: $2,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,768 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,767.95 |
| Education | $126.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $916.84 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $790.50 | 2021-2025 | Dupixent |
| Incyte Corporation | $635.39 | 2021-2025 | Opzelura |
| Pfizer INC. | $625.58 | 2021-2025 | |
| Janssen Biotech, INC. | $575.07 | 2023-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $549.18 | 2022-2025 | Sotyktu |
| Amgen INC. | $438.65 | 2021-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $433.30 | 2023-2024 | Vtama |
| Genzyme Corporation | $381.94 | 2023-2025 | |
| Ucb, INC. | $357.36 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $343.69 | 2021-2025 | |
| Galderma Laboratories, L.P. | $251.94 | 2023-2025 | Aklief, Nemluvio, Oracea |
| Lilly USA, LLC | $251.57 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $225.55 | 2021-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $202.34 | 2023-2025 | Zoryve |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $126.95 | 2023-2024 | |
| Sun Pharmaceutical Industries INC. | $108.58 | 2021-2025 | Winlevi, Absorica Ld |
| Epi Health, LLC | $103.30 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $100.48 | 2021-2025 | Jublia, Cabtreo, Arazlo |
| Almirall LLC | $93.43 | 2021-2023 | Klisyri, Seysara |
| Organon LLC | $91.67 | 2025 | Vtama, Nexplanon |
| Phadia US INC. | $49.50 | 2021-2023 | Immunocap |
| Verrica Pharmaceuticals INC. | $42.87 | 2023-2024 | Ycanth |
| Biofrontera INC. | $27.72 | 2022-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Medimetriks Pharmaceuticals, INC. | $23.17 | 2022 | |
| Revance Therapeutics, INC. | $23.12 | 2025 | Daxxify |
| Kyowa Kirin, INC. | $21.36 | 2021 | |
| Strata Skin Sciences, INC. | $19.61 | 2025 | Xtrac |
| Ani Pharmaceuticals, INC. | $17.98 | 2025 | Veregen |
| Lnhc, INC | $13.74 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Warnock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.